Zimbabwe has declined a major American healthcare agreement worth $367m (272 million pounds) spanning five years over Washington's request for sensitive information.
This move became public following a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government representative later stated that the US was requesting genetic material for scientific study and commercial purposes while was not willing to guarantee the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more dialogue to reach a deal acceptable to both sides so the country's vital HIV treatment initiative can continue.
Broader Background
This development comes after a comparable case in Kenya, where a high court halted a related deal with the US after concerns were filed about the safety of Kenyans' medical information.
After returning to office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
According to statements, 16 African countries have so far signed these new agreements, constituting over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, without any corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the end products would be accessible to our people should a future health crisis emerge."
National Interest and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending frameworks previously set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This framework is designed to ensure that when a nation provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to continued discussions with our US partners on how future co-operation might be arranged in a way that respects the independence and dignity of both nations."
Medical Community Reaction
Medical experts said it understood the official position, but recommended that talks need to persist given that much of the nation's HIV programmes were funded by foreign aid.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," the group commented.
This impasse emphasises the continuing tensions between accepting vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.